Cerus, Grifols to commercialize INTERCEPT Blood System

07/24/2007 | TradingMarkets.com

Cerus Corp. and Grifols S.A. have agreed to commercialize Cerus' INTERCEPT Blood System in Spain and Portugal. The system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a range of pathogens, including viruses, bacteria and parasites that might be present in donated blood.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI